Akira Sezai1, Motomi Shiono. 1. Department of Cardiovascular Surgery, Nihon University School of Medicine, Tokyo, Japan.
Abstract
PURPOSE: In 2014, the American Heart Association (AHA)/American College of Cardiology (ACC) guidelines were largely revised with regard to the selection of prosthetic valves. (1) A mechanical prosthesis is reasonable for aortic valve replacement (AVR) or mitral valve replacement (MVR) in patients less than 60 years of age, (2) A bioprosthesis is reasonable in patients more than 70 years of age, and (3) Either a bioprosthetic or mechanical valve is reasonable in patients between 60 and 70 years of age.Japan faces the unprecedented population aging, and moreover, the average life expectancy is longer among the Japanese than the Westerners. In Japan, whether this choice is appropriate seems questionable. METHODS: This time, with the revision of the AHA/ACC guidelines, it might be necessary to take into consideration the average life expectancy of Japanese people and revise the Japanese guidelines accordingly. RESULTS: We should consider whether 60-70 years should be set as a gray zone regarding the age criteria for choosing biological valves, or if the age should be set higher relative to that specified in the western guidelines, given the longer Japanese life expectancy. CONCLUSION: We believe that the development of unique, Japanese guidelines for the selection of prosthetic valves will allow us to provide appropriate selection and treatment for each patient.
PURPOSE: In 2014, the American Heart Association (AHA)/American College of Cardiology (ACC) guidelines were largely revised with regard to the selection of prosthetic valves. (1) A mechanical prosthesis is reasonable for aortic valve replacement (AVR) or mitral valve replacement (MVR) in patients less than 60 years of age, (2) A bioprosthesis is reasonable in patients more than 70 years of age, and (3) Either a bioprosthetic or mechanical valve is reasonable in patients between 60 and 70 years of age.Japan faces the unprecedented population aging, and moreover, the average life expectancy is longer among the Japanese than the Westerners. In Japan, whether this choice is appropriate seems questionable. METHODS: This time, with the revision of the AHA/ACC guidelines, it might be necessary to take into consideration the average life expectancy of Japanese people and revise the Japanese guidelines accordingly. RESULTS: We should consider whether 60-70 years should be set as a gray zone regarding the age criteria for choosing biological valves, or if the age should be set higher relative to that specified in the western guidelines, given the longer Japanese life expectancy. CONCLUSION: We believe that the development of unique, Japanese guidelines for the selection of prosthetic valves will allow us to provide appropriate selection and treatment for each patient.
Authors: R Scott McClure; Narendren Narayanasamy; Esther Wiegerinck; Stuart Lipsitz; Ann Maloney; John G Byrne; Sary F Aranki; Gregory S Couper; Lawrence H Cohn Journal: Ann Thorac Surg Date: 2010-05 Impact factor: 4.330
Authors: Rick A Nishimura; Catherine M Otto; Robert O Bonow; Blase A Carabello; John P Erwin; Robert A Guyton; Patrick T O'Gara; Carlos E Ruiz; Nikolaos J Skubas; Paul Sorajja; Thoralf M Sundt; James D Thomas Journal: Circulation Date: 2014-03-03 Impact factor: 29.690
Authors: J Matthew Brennan; Fred H Edwards; Yue Zhao; Sean O'Brien; Michael E Booth; Rachel S Dokholyan; Pamela S Douglas; Eric D Peterson Journal: Circulation Date: 2013-03-28 Impact factor: 29.690
Authors: Paolo Stassano; Luigi Di Tommaso; Mario Monaco; Francesco Iorio; Paolo Pepino; Nicola Spampinato; Carlo Vosa Journal: J Am Coll Cardiol Date: 2009-11-10 Impact factor: 24.094
Authors: D M Nicoloff; R W Emery; K V Arom; W F Northrup; C R Jorgensen; Y Wang; W G Lindsay Journal: J Thorac Cardiovasc Surg Date: 1981-11 Impact factor: 5.209